熱門資訊> 正文
Amicus从杰富瑞收购开始，被视为“以合理价格增长”
2024-09-07 00:49
- Jefferies initiated coverage of Amicus Therapeutics (NASDAQ:FOLD) with a buy rating, calling the stock “growth at a reasonable price.”
- The investment bank said the rare disease drug developer was a SMID cap “on the cusp of transitioning from value to growth.”
- Jeffries sees the stock as trading near its view of the Fabry base business, noting it believes generics will launch later than the consensus view, with the Pompe launch growing to be a $750M+ franchise “that’s practically free at current valuation.
- The investment bank set its price target for the stock at $18.
More on Amicus Therapeutics
- Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
- Amicus Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
- Amicus Therapeutics, Inc. (FOLD) Q2 2024 Earnings Call Transcript
- Amicus Therapeutics Q2 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Amicus Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
